Doximity, Inc.
- Open
- 22.03
- Day high
- 22.30
- Day low
- 21.50
- Prev close
- 22.21
- Volume
- 2.1M
- Mkt cap
- $4.0B
- P/E (TTM)
- 20.7
- EPS (TTM)
- $1.04
- P/B
- 4.2
- P/S
- 6.2
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$395K over the last 3 months (0 open-market buys, 4 sales)
- 🏛Institutions mixed (13F)
Doximity, Inc. (DOCS) is a Healthcare company listed on NYSE. The stock is down 64% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 4 sales (SEC Form 4).
Doximity, Inc. (DOCS) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 16 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
DOCS earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 13, 2026 | $0.28 | $0.26 | -7.1% | $145M | +0.9% |
| Feb 5, 2026 | $0.44 | $0.46 | +4.5% | $185M | +27.9% |
| Nov 6, 2025 | $0.38 | $0.45 | +18.8% | $169M | +6.7% |
| Aug 7, 2025 | $0.30 | $0.36 | +19.4% | $146M | +4.6% |
| May 15, 2025 | $0.27 | $0.38 | +39.9% | $138M | +3.4% |
| Feb 6, 2025 | $0.31 | $0.45 | +45.2% | $169M | +25.7% |
| Nov 7, 2024 | $0.25 | $0.30 | +20.0% | $137M | +7.6% |
| May 16, 2024 | $0.20 | $0.25 | +25.0% | $118M | +1.4% |
| Feb 8, 2024 | $0.23 | $0.29 | +26.1% | $135M | +16.3% |
| Nov 9, 2023 | $0.18 | $0.22 | +22.2% | $114M | +4.2% |
| May 16, 2023 | $0.17 | $0.20 | +17.6% | $111M | +3.3% |
| Feb 9, 2023 | $0.18 | $0.22 | +22.2% | $115M | +4.7% |
DOCS insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 18, 2026 | ZATZ STEVEN Lofficer: President | Grant | 55,524 | — |
| Jun 10, 2026 | Sitaram Siddharthofficer: Interim PAO | Sell | 2,444 | $20.41 |
| Jun 10, 2026 | Sitaram Siddharthofficer: Interim PAO | Option | 5,000 | $4.12 |
| May 19, 2026 | Tangney Jeffreydirector, 10 percent owner, officer: Chief Executive Officer | Tax | 14,964 | $18.01 |
| May 19, 2026 | Sitaram Siddharthofficer: Interim PFO and PAO | Tax | 1,246 | $18.01 |
| May 19, 2026 | Tangney Jeffreydirector, 10 percent owner, officer: Chief Executive Officer | Grant | 322,614 | — |
| May 13, 2026 | Sitaram Siddharthofficer: Interim PFO and PAO | Sell | 2,309 | $25.77 |
| May 13, 2026 | Sitaram Siddharthofficer: Interim PFO and PAO | Option | 5,000 | $4.12 |
| May 8, 2026 | Wampler Kira Schererdirector | Option | 9,000 | $1.54 |
| May 8, 2026 | Wampler Kira Schererdirector | Sell | 9,000 | $26.06 |
| Apr 14, 2026 | Sitaram Siddharthofficer: Interim PFO and PAO | Sell | 2,427 | $21.09 |
| Apr 14, 2026 | Sitaram Siddharthofficer: Interim PFO and PAO | Option | 5,000 | $4.12 |
| Mar 12, 2026 | Sitaram Siddharthofficer: Interim PFO and PAO | Sell | 2,282 | $27.88 |
| Mar 12, 2026 | Sitaram Siddharthofficer: Interim PFO and PAO | Option | 5,000 | $4.12 |
| Mar 12, 2026 | Sitaram Siddharthofficer: Interim PFO and PAO | Sell | 2,319 | $25.37 |
Source: DOCS SEC Form 4 filings, latest Jun 18, 2026. For informational purposes only — not investment advice.
See the full DOCS insider & 13F page →Doximity, Inc. company profile
Overview
Doximity, Inc. (NYSE:DOCS) is a San Francisco-based healthcare technology company that operates the largest professional medical network in the United States. Founded in 2010 as 3MD Communications, Inc. and renamed to Doximity in the same year, the company went public in June 2021. Doximity has established itself as the leading digital platform connecting medical professionals, serving over one million healthcare providers including physicians, nurse practitioners, and physician assistants across the country.
Business
Doximity operates in the healthcare information services industry, providing a cloud-based digital platform specifically designed for medical professionals. The company's core offering is essentially a professional social network for healthcare providers, similar to LinkedIn but tailored exclusively for the medical field. The platform serves two primary functions. For healthcare professionals, it provides tools for professional networking, continuing medical education, telehealth services, patient care coordination, and career management. Medical professionals use Doximity to stay current with medical research, communicate securely with colleagues, conduct virtual patient visits, and manage their professional profiles and career opportunities. For pharmaceutical companies and healthcare systems, Doximity serves as a sophisticated marketing and communication platform. Pharmaceutical manufacturers use the platform to reach healthcare providers with targeted educational content, drug information, and promotional materials in a clinical context. The platform's newsfeed delivers medical news and research to over 900,000 unique prescribers, while workflow tools including AI-powered features, telehealth capabilities, messaging, and scheduling are used by over 600,000 unique active prescribers. The company has two main business segments: the pharmaceutical segment, which generates approximately 85-90% of revenue through subscription-based services to drug manufacturers, and the medical recruitment segment, which connects healthcare professionals with career opportunities and generates roughly 10-15% of revenue.
Competitive moat
Doximity possesses a strong competitive moat built primarily on network effects and switching costs. As the largest professional medical network in the United States with over one million healthcare professionals, the platform becomes more valuable as more users join, creating a powerful network effect. Healthcare providers are drawn to the platform because their colleagues are already there, while pharmaceutical companies want access to this concentrated audience of medical professionals. The company has built significant switching costs through its integrated workflow tools, including AI-powered features, telehealth capabilities, secure messaging, and scheduling tools that have become embedded in healthcare providers' daily routines. With over 600,000 unique active prescribers using these workflow tools, replacing Doximity would require significant disruption to established professional workflows. Doximity's moat is further strengthened by its reputation for maintaining a high-integrity, clinically-focused environment that healthcare professionals trust. This trust is difficult for competitors to replicate and is reinforced by the platform's focus on medical education and professional development rather than general social networking. However, the moat faces potential challenges from large technology companies like Microsoft, Google, or Amazon who could leverage their resources to build competing platforms. Electronic health record (EHR) companies could also integrate similar networking and communication features directly into their systems. Additionally, if pharmaceutical marketing regulations change significantly, it could alter the competitive landscape. Despite these potential threats, Doximity's established network effects and deep integration into healthcare workflows provide substantial defensive advantages.
Risks & safety
Doximity demonstrates a strong margin of safety with robust financial metrics and conservative capital structure. • **Cash Position**: $209.6 million in cash and short-term investments with minimal debt (debt-to-equity ratio of 0.011) • **Profitability**: Strong free cash flow generation of $273.3 million in fiscal 2025, with consistent positive cash flow from operations • **Liquidity**: Current ratio of 6.97 indicates excellent short-term liquidity with no solvency concerns • **Valuation Metrics**: Trading at 48.6x P/E ratio and 46.7x EV/EBITDA, which appears elevated but justified by strong growth and market position • **Growth Trajectory**: 20% revenue growth in fiscal 2025 with 50% EBITDA margins demonstrating operational efficiency • **Balance Sheet**: Total assets of $1.26 billion against total liabilities of only $181.7 million, providing substantial financial cushion • **Business Model**: Subscription-based revenue (93% of total) provides predictable cash flows and high visibility The primary risk is valuation sensitivity to growth expectations, but the strong balance sheet and cash generation provide significant downside protection.
Recent development
Over the past few years, Doximity has undergone significant strategic evolution, transforming from primarily a professional networking platform to a comprehensive healthcare workflow and AI-powered solution provider. The company has made substantial investments in artificial intelligence, launching Doximity GPT and other AI-powered tools that have seen explosive growth, with AI tool usage growing over 5x year-over-year and completing over 1.8 million prompts. A major strategic initiative has been the development and rollout of the client portal, which now serves over 50% of pharmaceutical brand clients. This portal provides real-time analytics, daily updates, and actionable recommendations, enabling more sophisticated pricing strategies and improved client relationships. The portal has facilitated the introduction of integrated programs that combine multiple marketing modules for more comprehensive client solutions. The company has significantly expanded its product portfolio, with point-of-care and formulary products growing over 100% year-over-year and now representing 20% of pharmaceutical sales. These workflow tools, including telehealth capabilities, secure messaging, and scheduling features, are being used by over 620,000 unique active prescribers and are positioned to potentially become as significant as the newsfeed business within 3-5 years. Doximity has also pursued strategic acquisitions, including Amion.com for physician scheduling capabilities, and launched new initiatives like NP Navigator to help nurse practitioners find training programs. The company has expanded its focus beyond physicians to include nurse practitioners and physician assistants, with over 60% of these professionals now on the platform.
DOCS company profile · for informational purposes only — not investment advice.
Track DOCS with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free